Jonathan D. Campbell

Best Publications

• Multiple sclerosis prevalence in the United States commercially insured population

  Piyameth Dilokthornsakul;Robert J. Valuck;Kavita V. Nair;John R. Corboy

  304
  Citations

• The costs of treating breast cancer in the US: a synthesis of published evidence.

  Jonathan D. Campbell;Scott D. Ramsey;Scott D. Ramsey

  164
  Citations

• Community Health Worker Home Visits for Medicaid-Enrolled Children With Asthma: Effects on Asthma Outcomes and Costs.

  Jonathan D. Campbell;Marissa Brooks;Patrick Hosokawa;June Robinson

  158
  Citations

• Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates

  Jonathan D. Campbell;Vahram Ghushchyan;R. Brett McQueen;Sharon Cahoon-Metzger

  150
  Citations

• Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis.

  William V. Padula;Shiona Heru;Jonathan D. Campbell

  145
  Citations

• Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries.

  Bertalan Németh;Anett Molnár;Sándor Bozóki;Sándor Bozóki;Kalman Wijaya

  134
  Citations

• Asthma outcomes: Healthcare utilization and costs

  Lara J. Akinbami;Sean D. Sullivan;Jonathan D. Campbell;Robert W. Grundmeier

  110
  Citations

• The promise of Immuno-oncology: implications for defining the value of cancer treatment.

  Howard L. Kaufman;Michael B. Atkins;Prasun Subedi;James Wu

  108
  Citations

• Validation of an algorithm for identifying MS cases in administrative health claims datasets

  William J. Culpepper;Ruth Ann Marrie;Annette Langer-Gould;Mitchell T. Wallin

  100
  Citations

• Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke

  Michelle H. Leppert;Jonathan D. Campbell;Jennifer R. Simpson;James F. Burke

  99
  Citations

• The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.

  J. D. Campbell;D. E. Spackman;S. D. Sullivan

  98
  Citations

• Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Jeffrey A. Tice

  95
  Citations

• Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations

  R Brett McQueen;Danielle N Sheehan;Melanie D Whittington;Job F M van Boven

  94
  Citations

• Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?

  Anne Mason;Michael Drummond;Scott Ramsey;Jonathan Campbell

  89
  Citations

• Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes

  R Brett McQueen;Samuel L Ellis;Jonathan D Campbell;Kavita V Nair

  83
  Citations

• Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Varun M. Kumar

  81
  Citations

• Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.

  Melanie D Whittington;R Brett McQueen;Daniel A Ollendorf;Varun M Kumar

  77
  Citations

• Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder.

  Jonathan H. Watanabe;Jonathan D. Campbell;Arliene Ravelo;Michael B. Chancellor

  70
  Citations

• Adherence to Statins in Primary Prevention: Yearly Adherence Changes and Outcomes

  Julia F. Slejko;P. Michael Ho;Heather D. Anderson;Kavita V. Nair

  68
  Citations

• Measuring the cost of poor asthma control and exacerbations

  Patrick W Sullivan;Vahram H Ghushchyan;Jonathan D Campbell

  51
  Citations